CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,362 enrolled
Drug / intervention
hemoperfusion combined with hemodialysis +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03227770
NCT03227770N/ACompleted
CompareCT.gov

A Randomized, Open-label, Multi-centre Trial Comparing Hemodialysis Plus Hemoperfusion Versus Hemodialysis Alone in Adult Patients With End-stage Renal Disease (HD/HPvsHD)

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine·interventional·Posted Jul 24, 2017·Updated Aug 29, 2022

In Brief

A clinical study evaluating hemoperfusion combined with hemodialysis and hemodialysis for End-stage Renal Disease. Completed, enrolled 1,362 participants across 11 sites.

Detailed Summary

This multi-center, open-label, randomized controlled trial aims to investigate the efficacy of hemoperfusion (HP) combined with hemodialysis (HD) by evaluating all-cause mortality and cardiovascular mortality in maintenance hemodialysis patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-stage Renal Disease
CountriesChina
CollaboratorsShanghai Zhongshan Hospital, RenJi Hospital, Ruijin Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Changhai Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai University of Traditional Chinese Medicine, Shanghai Tongji Hospital, Tongji University School of Medicine, Yangpu District Central Hospital Affiliated to Tongji University

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 24, 2017
Enrollment StartDec 1, 2017
Primary CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.9 years ago

Interventions

hemoperfusion combined with hemodialysisdevice

Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)

hemodialysisdevice

Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week